Insider Transactions in Q4 2024 at Nektar Therapeutics (NKTR)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 24
2024
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
16,560
-4.71%
|
$0
$0.89 P/Share
|
|
Dec 23
2024
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
33,402
-8.67%
|
$0
$0.9 P/Share
|
|
Dec 19
2024
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
51,115
-13.52%
|
$0
$0.94 P/Share
|
|
Dec 18
2024
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
85,035
-7.11%
|
$0
$0.99 P/Share
|
|
Dec 17
2024
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
46,995
-3.78%
|
$46,995
$1.01 P/Share
|
|
Dec 13
2024
|
Mark Andrew Wilson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
165,938
+30.1%
|
-
|
|
Dec 13
2024
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+26.31%
|
-
|
|
Dec 13
2024
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
410,625
+24.84%
|
-
|
|
Nov 19
2024
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
16,278
-1.92%
|
$16,278
$1.01 P/Share
|
|
Nov 19
2024
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,407
-2.84%
|
$6,407
$1.01 P/Share
|
|
Nov 19
2024
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
7,785
-3.1%
|
$7,785
$1.01 P/Share
|